Our next guest says this move makes Fiser a more credible threat in the obesity landscape. For more, let's bring in Evan Seagerman, head of healthcare research at Beimo Capital Markets. Evan, great to have you with us.Um, you better you've got a buy rating on on Fizer and a $30 price target. I'm wondering buying this portfolio of very experimental obesity drugs, i.e. phase one drugs effectively. Does this make you a lot more bullish.I am bullish because I think Fizer's foray into obesity has been we've been ...